Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Upper respiratory tract infection? 645 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 645 reports of Upper respiratory tract infection have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 1.0% of all adverse event reports for OMALIZUMAB.

645
Reports of Upper respiratory tract infection with OMALIZUMAB
1.0%
of all OMALIZUMAB reports
16
Deaths
285
Hospitalizations

How Dangerous Is Upper respiratory tract infection From OMALIZUMAB?

Of the 645 reports, 16 (2.5%) resulted in death, 285 (44.2%) required hospitalization, and 16 (2.5%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for OMALIZUMAB.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which OMALIZUMAB Alternatives Have Lower Upper respiratory tract infection Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection OMALIZUMAB Demographics